The a2 Milk Company Limited

A2M.AX Q4 2026

Reported: 2026-08-18

The stock dropped 3.3% as investors reacted to the clearly disappointing impact of supply chain disruptions on China label infant milk formula (IMF) sales and increased costs, alongside cautious guidance for FY '27 with materially weighted second-half revenue and margins expected.

Key takeaways

Group revenue grew 12.4% to $1.95 billion; underlying EBITDA rose 5.4% excluding losses from a2 Pokeno, but reported EBITDA declined 2.5% to $284 million.
China IMF sales grew 5% in a flat market but were significantly affected in the second half by supply chain disruptions causing product availability issues, lost market share, and increased costs.
Other nutritionals surged 42% and liquid milk advanced 22%, supporting broad-based growth across regions, including 28% growth in the U.S.
FY '27 guidance anticipates mid-single-digit revenue growth, with performance materially weighted to the second half; first half EBITDA margin expected to be down significantly versus prior year before improvement.
The company outlined a recovery plan focused on rebuilding trust and market share in China, with early progress noted but uncertainty remains about the pace of recovery.

View recap

Braskem S.A.

BAK Q2 2026

Reported: 2026-08-18

Shares declined 2.9% following Q2 results as investors weighed the combination of volume softness in Brazil and maintenance-related headwinds in the U.S. and Europe, despite some margin improvement from favorable spreads and one-time credits. The market appears cautious amid mixed operational signals and currency pressures.

Key takeaways

Brazil segment's resale volumes declined (polyethylene down 6%, PVC down 1%, chemicals down 4%) despite a 1 percentage point gain in plant utilization; resin sales reduced by imports.
Recurring EBITDA in Brazil surged 261% to $869 million, driven by a 50% increase in international spreads, $115 million in tax credits (PIS/COFINS), and $27 million from recovery and provision reversals.
U.S. and Europe segment saw utilization drop 3 points to 76% due to scheduled maintenance downtime, with sales volume flat quarter-over-quarter but mixed by higher U.S. volumes and lower European sales. Reported EBITDA rose to $147 million, supported by higher polypropylene spreads.
Green polyethylene sales spiked 49%, aided by normalization of demand post-Chinese New Year and expanded partnerships (e.g., New Balance).
Currency headwinds compounded results, with a 4% appreciation of the Brazilian real versus the U.S. dollar partially offsetting margin gains.

View recap

Credicorp Ltd.

BAP Q2 2026

Reported: 2026-08-18

Credicorp’s shares rose modestly by 0.8% following Q2 results that broadly met expectations, reflecting steady execution and confidence in Peru’s improving economic outlook, though the market showed little enthusiasm amid cautious near-term risks related to El Nino.

Key takeaways

Reported a return on equity of 20.3%, driven by a diversified business model and solid core performances.
Risk-adjusted net interest margin stood at 5.5%, supported by low-cost funding and a healthy portfolio mix.
Innovation contributed 9.9% of risk-adjusted revenues, indicating ongoing progress in diversifying earnings.
Efficiency ratio remained at 45.4%, with continued investments in digital capabilities and customer engagement.
Management reiterated confidence in Peru’s medium-term outlook and increased medium-term ROE target from ~19.5% to ~22%, but noted El Nino as a manageable near-term risk.

View recap

Companhia Energetica de Minas Gerais

CIG Q2 2026

Reported: 2026-08-18

Cemig's shares declined 1.5% following its Q2 report, reflecting investor caution despite solid investment execution and recurring EBITDA growth. The market reaction suggests muted confidence amid elevated financial expenses and a cautious outlook on near-term profitability.

Key takeaways

Recurring EBITDA increased by 9.3% year-over-year, demonstrating underlying operational stability.
Net income rose 15.6% year-over-year but was weighed down by higher financial expenses related to substantial funding to support CapEx.
Capital expenditures totaled BRL 3.3 billion in H1, representing 49% of the full-year BRL 6.7 billion target, focused mainly on distribution (BRL 2.6 billion).
Tariff adjustment for Cemig Distribution averaged +6.5%, supporting revenue growth in regulated segments.
Additional revenue from transmission investments contributed BRL 36 million in RAP this quarter, highlighting progress on infrastructure projects.

View recap

DeFi Technologies Inc.

DEFT Q2 2026

Reported: 2026-08-18

Shares fell 3.3% as investors reacted negatively to continued deceleration in assets under management and margin pressure driven by lower digital asset prices and compressing staking yields, signaling waning near-term growth prospects amid a challenging market environment.

Key takeaways

Average assets under management (AUM) declined to approximately $471.5 million, with quarter-end AUM dropping further to $397.2 million due to weak digital asset prices.
Total quarterly revenue fell to $7.8 million from $11.2 million in the prior period, primarily reflecting lower AUM and unfavorable mark-to-market adjustments on digital asset holdings.
Effective management fee yield remained near 1%, pressured by a higher weighting of lower-fee Bitcoin products and weak altcoin markets; staking yields declined to 2.4% amid lending rate compression and asset mix changes.
Net inflows for Valor totaled $22.8 million, indicating continued client interest despite market headwinds but insufficient to offset overall AUM declines.
The company maintained a strong liquidity position with $60.3 million in cash and equivalents, supplemented by $19.1 million in stretch preferred shares yielding 12%, indicating a disciplined approach to cash management despite the tougher operating environment.

View recap

freenet AG

FNTN.DE Q2 2026

Reported: 2026-08-18

The stock edged up by 0.9% following the earnings release, reflecting a broadly balanced investor response to stable subscriber additions and modest revenue growth, while concerns remain around ongoing margin pressures and ARPU stabilization.

Key takeaways

Added 140,000 subscribers in H1 2026, surpassing 10 million total, with net adds of 34,000 in Mobile and 35,000 in IPTV in Q2.
Postpaid service revenues increased by 0.7%, supported by a 1% front book price increase, offsetting prior ARPU declines.
Adjusted EBITDA grew close to 40% in H1, driven notably by the mobilezone acquisition and IPTV growth; however, margin impacts from a negative MNO agreement remain unresolved.
Marketing and sales expansion through mobilezone integration enhanced sales footprint and gross adds grew 11% YoY in Mobile.
Brand awareness remains low relative to competitors, with ongoing heavy investment aiming for longer-term improvements in direct customer acquisition and ARPU.

View recap

Global Water Resources, Inc.

GWRS Q2 2026

Reported: 2026-08-18

The stock rallied 13% following Q2 results driven by revenue growth supported by infrastructure coordination agreements, utility acquisitions, and organic connection growth that surpassed expectations.

Key takeaways

Total Q2 revenue rose 24.8% year-over-year to $17.8 million, including $2.1 million from infrastructure coordination and financing agreements (ICFAs).
Organic connection growth contributed a 2.7% increase in total active service connections to 69.4 thousand.
The company added 7 Tucson water systems acquired in mid-2025, enhancing its rate base.
Operating expenses were elevated due to increased depreciation from recent capital investments and growing medical costs.
A rate case settlement provides a clearer path to rate increases for key utilities, supporting medium-term earnings growth despite near-term margin pressure.

View recap

Nagarro SE

NA9.DE Q2 2026

Reported: 2026-08-18

Nagarro’s shares inched up just 0.2% following Q2 results that showed slowing revenue growth and modest margin improvement, reflecting a cautious market response amid a muted demand environment and ongoing geographic revenue headwinds.

Key takeaways

Q2 2026 revenue grew 2.0% in constant currency, down from 6.5% growth in Q1, evidencing deceleration in top-line momentum.
Revenue for the first half of 2026 grew 4.2% year-over-year on a constant currency basis.
Geographic performance was mixed: strong growth in the U.S. (+9.0%), India (+14.7%), and UAE (+16.8%), offset by declines in Germany (-3.8%) and Austria (-5.0%) attributed to client-specific factors.
Gross margin exceeded 32%, supported by favorable business mix and operational discipline.
Adjusted EBITDA margin reached 15.0%, partly aided by foreign exchange effects, with management acknowledging significant opportunities remain to improve sustainable profitability.

View recap

New Hope Corporation Limited

NHC.AX Q4 2026

Reported: 2026-08-18

Shares rose 4.9% on the back of better-than-expected pricing and production metrics, supporting a 30% quarterly EBITDA increase and reaffirming the company’s low-cost operational profile.

Key takeaways

Underlying EBITDA jumped 30% sequentially to $169 million, driven by improved realized coal pricing and favorable FX movements amid ongoing energy market volatility.
Saleable coal production increased 8% over the previous quarter to 2.3 million tonnes, with raw coal rising 16% due to moderated strip ratios at Bengalla Mine.
New Acland Mine posted a 3% rise in raw coal production but saw a 7% quarter-over-quarter dip in coal sales due to rail disruptions linked to industrial action.
Full-year saleable coal production reached 11.5 million tonnes, an 8% lift over 2025 and above guidance, including a 17% increase at New Acland.
Operational cash flow remains robust at $564 million for the year, supported by strong volumes and pricing, with $130 million capex guidance remaining for Manning Vale West pit development.

View recap

Outlook Therapeutics, Inc.

OTLK Q3 2026

Reported: 2026-08-18

Shares of Outlook Therapeutics plunged 24.4% following the quarter as investors reacted negatively to cautious commercial outlook and significant execution risks ahead despite FDA approval. The stock selloff reflects skepticism about the company’s ability to convert regulatory success into meaningful near-term revenue growth.

Key takeaways

FDA approved LYTENAVA, the first ophthalmic formulation of bevacizumab for wet AMD in the U.S., marking a regulatory milestone.
The total U.S. anti-VEGF retina market is estimated at $8.5 billion annually, with approximately 3.6 million injections of repackaged bevacizumab forecast in 2025.
Management projects LYTENAVA could generate over $500 million in peak annual sales by 2030 but emphasized this as a long-term goal requiring strong execution.
Key risks include uncertain commercial adoption dynamics, need for payer partnerships, access and reimbursement hurdles, and supply chain reliability.
No concrete near-term revenue or volume guidance was provided, highlighting the early stage of commercialization and investor caution.

View recap

PAVmed Inc.

PAVM Q2 2026

Reported: 2026-08-18

The stock rallied 12.3% post-earnings, driven primarily by tangible progress across PAVmed's product portfolio and encouraging regulatory milestones, particularly the potential for a faster FDA 510(k) pathway for PortIO.

Key takeaways

Lucid advances reimbursement and commercialization initiatives, notably securing positive coverage from the Laboratory Benefit Manager Concert and progress in VA commercialization.
Veris gains commercial momentum with increased patient onboarding at Ohio State University and targets early 2027 FDA 510(k) submission for its implantable monitor.
PortIO’s published first-in-human results support device safety and efficacy, with the potential regulatory pathway shifting favorably from De Novo to a shorter 510(k) process.
Octeris continues technical development with improved imaging speeds and prepares for clinical validation, targeting IRB approval and FDA pre-submission in the fourth quarter.
Financial updates included recent capital raises ($30M Series D preferred, $15M Senior Secured Note) used to retire previous preferred stock, strengthening the balance sheet.

View recap

Sidus Space, Inc.

SIDU Q2 2026

Reported: 2026-08-18

Sidus Space’s stock declined marginally by 0.2% after a quarter marked by capital raises and operational progression but without decisive commercial traction or updated financial guidance to materially shift investor expectations. The quarter represents a transition phase, with capital formation and operational milestones achieved, but lacking new growth drivers or guidance updates to catalyze a stronger market reaction.

Key takeaways

Raised approximately $159 million in gross proceeds through equity offerings in Q2, bolstering the balance sheet to fund commercialization.
Shifted focus from technological demonstration to scaling commercial applications, emphasizing recurring revenue and operating leverage.
Progressed satellite development with successful environmental qualification testing, clearing the path to launch.
Joined the Russell 3000, 2000, and Microcap indexes, increasing institutional visibility and potential investor base.
Management acknowledged dilution concerns but framed capital raises as necessary to advance commercialization rather than cover indefinite losses.

View recap

Super League Enterprise Inc. Common Stock

SLE Q2 2026

Reported: 2026-08-18

Shares declined 10.1% following the quarter, reflecting investor disappointment with flat gross revenue and a cautious outlook despite operational improvements and margin expansion.

Key takeaways

Gross revenue was roughly flat at $3 million year-over-year and sequentially, signaling stalled top-line growth amid challenging macro conditions including geopolitical uncertainty and shifts in advertising priorities.
Net revenue improved 16% sequentially to $1.24 million, driven by operational discipline and revenue quality initiatives.
Gross margin expanded to 41% from 36% in Q1, reflecting better cost management and efficiency gains in team utilization.
Adjusted EBITDA loss narrowed to $1.7 million from $2.1 million year-over-year, showing progress though still unprofitable.
Despite stable costs and expanded capabilities via the Misfits acquisition, investors appear skeptical about growth prospects given flat headline revenues and a tough external advertising environment.

View recap

Americas Gold and Silver Corporation

USAS Q2 2026

Reported: 2026-08-18

The stock gained modestly (+2.2%) as investors digested operational progress and ongoing infrastructure upgrades, though the market remained cautious without a clear catalyst to push shares materially higher.

Key takeaways

Consolidated silver production was approximately 665,000 ounces in Q2, supported by a 26% year-over-year increase at Cosala.
Revenue rose 71% year-over-year to $46.3 million, with the first half 2026 revenue totaling $114 million, up 126% from prior year.
Cosala cash costs improved to $16.91 per ounce, benefiting from higher grades and copper byproduct credits.
Galena Phase 2 shaft upgrades doubled hoisting capacity to a sustained 85 tonnes per hour, supporting planned production growth.
Resource conversion drilling showed promising silver grades 2-3x higher than previous resource estimates, potentially boosting reserves in 2027 mine plans.

View recap

Earnings Recaps

The a2 Milk Company Limited

Braskem S.A.

Credicorp Ltd.

Companhia Energetica de Minas Gerais

DeFi Technologies Inc.

freenet AG

Global Water Resources, Inc.

Nagarro SE

New Hope Corporation Limited

Outlook Therapeutics, Inc.

PAVmed Inc.

Sidus Space, Inc.

Super League Enterprise Inc. Common Stock

Americas Gold and Silver Corporation

Community

Earnings Recaps

The a2 Milk Company Limited

Braskem S.A.

Credicorp Ltd.

Companhia Energetica de Minas Gerais

DeFi Technologies Inc.

freenet AG

Global Water Resources, Inc.

Nagarro SE

New Hope Corporation Limited

Outlook Therapeutics, Inc.

PAVmed Inc.

Sidus Space, Inc.

Super League Enterprise Inc. Common Stock

Americas Gold and Silver Corporation

Community

Trending This Week

Notifications